Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney. (6th June 2022)

• Record Type: Journal Article
• Authors: Asaumi, Ryuta; Nunoya, Ken‐ichi; Yamaura, Yoshiyuki; Taskar, Kunal S.; Sugiyama, Yuichi
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 11:Number 7(2022)
• Page Start: 919
• Page End: 933
• Publication Date: 2022-06-06
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12807
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract: P‐glycoprotein (P‐gp) is an efflux transporter that plays an important role in the pharmacokinetics of its substrate, and P‐gp activities can be altered by induction and inhibition effects of rifampicin. This study aimed to establish a physiologically based pharmacokinetic (PBPK) model of rifampicin to predict the P‐gp‐mediated drug–drug interactions (DDIs) and assess the DDI impact in the intestine, liver, and kidney. The induction and inhibition parameters of rifampicin for P‐gp were estimated using two of seven DDI cases of rifampicin and digoxin and incorporated into our previously constructed PBPK model of rifampicin. The constructed rifampicin model was verified using the remaining five DDI cases with digoxin and five DDI cases with other P‐gp substrates (talinolol and quinidine). Based on the established PBPK model, following repeated dosing of 600 mg rifampicin, the deduced net effect was an approximately threefold induction in P‐gp activities in the intestine, liver, and kidney. Furthermore, in all 12 cases the predicted area under the plasma concentration–time curve ratios of the P‐gp substrates were within the predefined acceptance criteria with various dosing regimens. Intestinal effects of P‐gp–mediated DDIs had their greatest impact on the pharmacokinetics of digoxin and talinolol, with a minimal impact on the liver and kidney. For quinidine, predicted intestinal P‐gp/cytochrome P450 3A–mediated DDIs were slightly underestimated because of the complexity of nonlinearity and transporter‐enzyme interplay. These findings demonstrate that our rifampicin model can be applicable to quantitatively predict the net impact of P‐gp induction and/or inhibition on diverse P‐gp substrates and investigate the magnitude of DDIs in each tissue.